$2,317.53 travel Payment -- Novartis Pharmaceuticals to Dr. Jennifer Patel
Ophthalmologist Jennifer Patel Receives $2,317.53 in Travel Payments from Novartis for Ibrance
This page provides a detailed analysis of a $2,317.53 travel payment from Novartis Pharmaceuticals to Dr. Jennifer Patel. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $2,317.53 |
| Payment Type | travel |
| Payment Nature | Travel and Lodging |
| Pharmaceutical Company | Novartis Pharmaceuticals |
| Physician | Dr. Jennifer Patel |
| NPI Number | 1536677699 |
| Physician Specialty | Ophthalmology |
| Location | Springfield, MA |
| Date of Payment | 2024-08-28 |
| Related Drug/Device | Ibrance |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Novartis Pharmaceuticals made a $2.3K travel payment to Jennifer Patel, a Ophthalmology specialist in Springfield, MA. The payment was associated with Ibrance. Jennifer Patel received $2,317.53 from Novartis Pharmaceuticals for travel and lodging related to Ibrance. The payment occurred on August 28, 2024, and was for travel to Springfield, MA. This payment is categorized under 'Travel and Lodging' and is associated with the drug Ibrance.
Patient Guidance: What This Payment Means for You
This payment covers travel and lodging expenses related to medical education or research. It's important to understand how such payments might influence prescribing decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Travel and lodging payments are common in the pharmaceutical industry, particularly for educational events. The amount and nature of this payment should be considered in the context of typical industry practices for ophthalmology and the specific drug, Ibrance.
Regulatory Context: Sunshine Act Requirements
Payments made by manufacturers to physicians are subject to disclosure under the Sunshine Act (part of the Affordable Care Act), requiring transparency in financial relationships between industry and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- open-payments
- travel-lodging
- ophthalmology
- ibrance
- novartis
Understanding travel Payments
Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.
Frequently Asked Questions About This Payment
What was this $2.3K payment for?
This was a travel payment of $2.3K from Novartis Pharmaceuticals to Jennifer Patel, categorized as "Travel and Lodging". It was associated with Ibrance. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Jennifer Patel accept pharmaceutical money?
Yes, Jennifer Patel received this $2.3K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Jennifer Patel's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this travel payment?
A travel payment of $2.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Jennifer Patel's relationship with Novartis Pharmaceuticals?
The payment amount of $2,317.53 is specifically for travel and lodging. This $2.3K travel payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
Novartis Pharmaceuticals is the payer, and the payment is linked to Ibrance.
What should patients do after learning about this payment?
This payment covers travel and lodging expenses related to medical education or research. It's important to understand how such payments might influence prescribing decisions.
What else should I know about this travel payment?
The payment was made to Jennifer Patel, an Ophthalmologist, on August 28, 2024.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.